|
| Press Releases |
|
 |
|
| Tuesday, March 22, 2022 |
|
|
エーザイとバイオジェン、抗アミロイドβ（Aβ）プロトフィブリル抗体レカネマブに関する最新の知見を第16回アルツハイマー・パーキンソン病学会（AD/PD(TM) 2022）において発表 |
| more info >> |
|
|
Eisai: Latest Findings on Lecanemab Presented at AD/PD 2022 Annual Meeting |
| Eisai Co., Ltd. and Biogen Inc. announced today that the latest findings on lecanemab, an investigational anti-amyloid-beta (Abeta) protofibril antibody being developed for the treatment of early Alzheimer's disease (AD), were presented at the Abeta Targeted Therapies in AD 2 Symposium at the 2022 International Conference on Alzheimer's and Parkinson's Diseases (AD/PD) March 15-20 in Barcelona, Spain and virtually. more info >> |
|
| Wednesday, March 16, 2022 |
|
|
バイオジェンとエーザイはアルツハイマー病治療薬の提携契約を変更 |
| バイオジェン・インク（Nasdaq: BIIB、本社：米国マサチューセッツ州 ケンブリッジ、CEO：ミシェル・ヴォナッソス、以下 バイオジェン）とエーザイ株式会社（本社：東京都、代表執行役CEO：内藤晴夫、以下 エーザイ）は、このたび、既存のアデュカヌマブ（米国の製品名ADUHELM）のコラボレーション契約を変更したことをお知らせします。 more info >> |
|
| Tuesday, March 15, 2022 |
|
|
Eisai: Economic Arrangements of Amendment to Alzheimer's Disease Treatment Collaboration Agreement with Biogen |
| Eisai Co., Ltd. announced the following economic arrangements agreed in the amendment to Alzheimer's disease collaboration agreement with Biogen Inc. separately announced today. more info >> |
|
|
Biogen and Eisai Amend Collaboration Agreements on Alzheimer's Disease Treatments |
| Biogen Inc. and Eisai Co., Ltd. announced today that the companies have amended their existing collaboration agreement on aducanumab, which is commercialized in the United States as ADUHELM (aducanumab-avwa). more info >> |
|
| Friday, March 11, 2022 |
|
|
Eisai to Present New Lecanemab Data Exploring Distinct Mechanism of Action and Clinical Outcomes, Disease State (DSE) Symposium, and Other Pipeline Assets at the AD/PD 2022 Annual Meeting |
| Eisai Co., Ltd. announced today the company will present research from its robust Alzheimer's disease (AD) pipeline, including the latest findings on lecanemab, Eisai's investigational anti-amyloid beta (Abeta) protofibril antibody for the treatment of early AD at the AD/PD 2022 International Conference on Alzheimer's and Parkinson's Diseases (AD/PD) from March 15-20 in Barcelona, Spain and virtually. more info >> |
|
| Wednesday, March 9, 2022 |
|
|
Eisai Certified as the 2022 Health and Productivity Management Outstanding Organization (White 500) |
| Eisai Co., Ltd. announced today that it has been certified as the Health and Productivity Management Outstanding Organization in the large enterprise category (White 500) by Japan's Ministry of Economy, Trade and Industry and the Nippon Kenko Kaigi. more info >> |
|
| Monday, March 7, 2022 |
|
|
LENVIMA in Combination with KEYTRUDA Approved In Taiwan for the Treatment of Patients with Advanced Endometrial Carcinoma |
| Eisai Co., Ltd. announced today that LENVIMA (generic name: lenvatinib mesylate), the multiple receptor tyrosine kinase inhibitor discovered by Eisai, in combination with Merck & Co., Inc., Kenilworth, N.J., U.S.A. more info >> |
|
|
エーザイ、「レンビマ(R)」「キイトルーダ(R)」との併用療法について、治療ラインに関らず全身療法後に増悪した、根治的手術または放射線療法に不適応な進行性子宮内膜がんの適応で、台湾において承認を取得 |
| エーザイ株式会社（本社：東京都、代表執行役CEO：内藤晴夫、以下 エーザイ）は、このたび、自社創製のチロシンキナーゼ阻害剤「レンビマ(R)」（一般名：レンバチニブメシル酸塩）について、Merck & Co., Inc. Kenilworth, N.J., U.S.A.（北米以外ではMSD）の抗PD-1抗体「キイトルーダ(R)」（一般名：ペムブロリズマブ）との併用療法による治療ラインに関らず全身療法後に増悪した、根治的手術または放射線療法に不適応な進行性子宮内膜がんの適応で、台湾において承認を取得したことをお知らせします。 more info >> |
|
| Friday, March 4, 2022 |
|
|
エーザイとバイオジェン、「レカネマブ」について日本での早期承認取得をめざし、医薬品事前評価相談制度に基づく申請データの提出を開始 |
| エーザイ株式会社（本社：東京都、代表執行役CEO：内藤晴夫、以下 エーザイ）とバイオジェン・インク （Nasdaq: BIIB、本社：米国マサチューセッツ州ケンブリッジ、CEO：ミシェル・ヴォナッソス、以下 バイオジェン）は、このたび、エーザイが、抗アミロイドβ（Aβ）プロトフィブリル抗体レカネマブ（開発品コード：BAN2401）について、日本において医薬品事前評価相談制度に基づき、独立行政法人医薬品医療機器総合機構（PMDA）に申請データの提出を開始したことをお知らせします。 more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
Business of IP Asia (BIP Asia) Forum and Entrepreneur Day open today
Dec 5, 2025 15:41 HKT/SGT
|
|
|
心系大埔火災災情 斯派柯急援300萬港元助重建
Dec 5, 2025 15:13 HKT/SGT
|
|
|
三菱造船と日本製鉄が低圧液化CO₂タンクの新規鋼材と熱処理（PWHT）省略技術を開発
Dec 5, 2025 11:30: JST
|
|
|
LEXUS、バッテリーEVスポーツカーのコンセプトモデル「Lexus LFA Concept」を世界初公開
Dec 5, 2025 11:20: JST
|
|
|
Business of IP Asia (BIP Asia) Forum and Entrepreneur Day open today
Dec 4, 2025 22:00: JST
|
|
|
Doubleview Extends High-Grade Domains at Hat: H099 Returns 438m of 0.40% CuEq Including 52m of 1.02% CuEq, Expanding Mineralization Envelope Around Conceptual Pit Vertically and Laterally
Dec 4, 2025 21:59 HKT/SGT
|
|
|
CaoCao Unveils '100 Cities, 100 Billion in 10 Years' Robotaxi Strategy, Officially Launches World's First 'Green Intelligent Mobility Hub'
Dec 4, 2025 21:00 HKT/SGT
|
|
|
曹操出行發佈Robotaxi「十年百城千億」戰略目標 全球首個「綠色智慧通行島」正式啟用
Dec 4, 2025 18:18 HKT/SGT
|
|
|
The Gourmet's Guide: Using Your TravelKon eSIM to Hunt for Japan's Best Ramen, Sushi, and Street Food
Dec 4, 2025 17:45 HKT/SGT
|
|
|
Spritzer Celebrates Global and Regional Brand Excellence 2025
Dec 4, 2025 12:45 HKT/SGT
|
|
|
Honda、新型「CR-V」の先行予約開始
Dec 4, 2025 11:30: JST
|
|
|
在聯泓格潤「超級工廠」看見綠色材料全鏈路
Dec 4, 2025 09:36 HKT/SGT
|
|
|
在联泓格润"超级工厂" 看见绿色材料全链路
Dec 4, 2025 09:14 HKT/SGT
|
|
|
阿曼十年黃金居留計劃吸引全球投資者尋求穩定與長期通達
Dec 4, 2025 08:00 HKT/SGT
|
|
|
阿曼十年黄金居留计划吸引全球投资者寻求稳定与长期准入
Dec 4, 2025 08:00 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
